Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD)

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CV) often coexist. COPD and CVD are complex diseases characterized by a strict interaction between environment and genetic. The mechanisms linking these two diseases are complex, multifactorial and not entirely understood, influencing the therapeutic approach. COPD is characterized by several comorbidities, it is hypothesizable that treatment of cardiovascular co-morbidities may reduce morbidity and mortality. Flavonoids are an important class of plant low molecular weight secondary metabolites (SMs). Convincing data from laboratory, epidemiological, and human clinical studies point to an important effects on CVD risk prevention.

OBJECTIVE: This review aims to provide up-to-date information on the ability of Flavonoids to reduce the CVD risk.

CONCLUSIONS: Current studies support the potential of Flavonoids to prevent the risk of CVD. Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids for managing CVD comorbidity in COPD.

Original languageEnglish
JournalCurrent Medicinal Chemistry
DOIs
Publication statusE-pub ahead of print - May 13 2018

Fingerprint

Pulmonary diseases
Flavonoids
Chronic Obstructive Pulmonary Disease
Cardiovascular Diseases
Comorbidity
Morbidity
Metabolites
Molecular Weight
Mortality
Molecular weight

Cite this

@article{58c6ff566fcf4af5b0483df7b60fba8d,
title = "Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD)",
abstract = "BACKGROUND: Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CV) often coexist. COPD and CVD are complex diseases characterized by a strict interaction between environment and genetic. The mechanisms linking these two diseases are complex, multifactorial and not entirely understood, influencing the therapeutic approach. COPD is characterized by several comorbidities, it is hypothesizable that treatment of cardiovascular co-morbidities may reduce morbidity and mortality. Flavonoids are an important class of plant low molecular weight secondary metabolites (SMs). Convincing data from laboratory, epidemiological, and human clinical studies point to an important effects on CVD risk prevention.OBJECTIVE: This review aims to provide up-to-date information on the ability of Flavonoids to reduce the CVD risk.CONCLUSIONS: Current studies support the potential of Flavonoids to prevent the risk of CVD. Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids for managing CVD comorbidity in COPD.",
author = "Patrizia Russo and Giulia Prinzi and Palma Lamonaca and Vittorio Cardaci and Massimo Fini",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
month = "5",
day = "13",
doi = "10.2174/0929867325666180514100640",
language = "English",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD)

AU - Russo, Patrizia

AU - Prinzi, Giulia

AU - Lamonaca, Palma

AU - Cardaci, Vittorio

AU - Fini, Massimo

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018/5/13

Y1 - 2018/5/13

N2 - BACKGROUND: Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CV) often coexist. COPD and CVD are complex diseases characterized by a strict interaction between environment and genetic. The mechanisms linking these two diseases are complex, multifactorial and not entirely understood, influencing the therapeutic approach. COPD is characterized by several comorbidities, it is hypothesizable that treatment of cardiovascular co-morbidities may reduce morbidity and mortality. Flavonoids are an important class of plant low molecular weight secondary metabolites (SMs). Convincing data from laboratory, epidemiological, and human clinical studies point to an important effects on CVD risk prevention.OBJECTIVE: This review aims to provide up-to-date information on the ability of Flavonoids to reduce the CVD risk.CONCLUSIONS: Current studies support the potential of Flavonoids to prevent the risk of CVD. Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids for managing CVD comorbidity in COPD.

AB - BACKGROUND: Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CV) often coexist. COPD and CVD are complex diseases characterized by a strict interaction between environment and genetic. The mechanisms linking these two diseases are complex, multifactorial and not entirely understood, influencing the therapeutic approach. COPD is characterized by several comorbidities, it is hypothesizable that treatment of cardiovascular co-morbidities may reduce morbidity and mortality. Flavonoids are an important class of plant low molecular weight secondary metabolites (SMs). Convincing data from laboratory, epidemiological, and human clinical studies point to an important effects on CVD risk prevention.OBJECTIVE: This review aims to provide up-to-date information on the ability of Flavonoids to reduce the CVD risk.CONCLUSIONS: Current studies support the potential of Flavonoids to prevent the risk of CVD. Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids for managing CVD comorbidity in COPD.

U2 - 10.2174/0929867325666180514100640

DO - 10.2174/0929867325666180514100640

M3 - Article

C2 - 29756566

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

ER -